Association Between Trendelenburg Sign and Lumbar MRI Abnormalities

June 1, 2026 updated by: Zeynep Iyigun, Bahçeşehir University

Association of the Trendelenburg Sign With Spinopelvic Biomechanics and Lumbar MRI Abnormalities"

The Trendelenburg sign is a common clinical finding indicating hip abductor dysfunction and altered pelvic stability. The relationship between the Trendelenburg sign, spinopelvic biomechanics, hip muscle strength, and lumbar magnetic resonance imaging (MRI) abnormalities remains insufficiently understood. This study aims to investigate the association between Trendelenburg sign positivity and lumbar MRI findings, including facet arthropathy, ligamentum flavum hypertrophy, multifidus muscle morphology, and psoas muscle characteristics, as well as spinopelvic biomechanical parameters and hip abductor muscle strength.

Study Overview

Status

Not yet recruiting

Detailed Description

The Trendelenburg sign is a clinical indicator of hip abductor muscle dysfunction and altered pelvic stability. Changes in hip abductor function may affect spinopelvic biomechanics and contribute to lumbar degenerative changes. This prospective observational study aims to investigate the association between Trendelenburg sign positivity and lumbar MRI abnormalities in adults with chronic low back pain.

Participants will be classified as Trendelenburg-positive or Trendelenburg-negative based on clinical examination. Hip abductor muscle strength and lumbar MRI findings will be evaluated. MRI parameters will include the presence and severity of facet joint arthropathy, ligamentum flavum thickness, multifidus muscle thickness, and psoas muscle characteristics.

The primary objective is to determine whether a positive Trendelenburg sign is associated with lumbar facet arthropathy. Secondary objectives include evaluating the relationships between the Trendelenburg sign, hip abductor strength, and other lumbar MRI parameters. The findings may improve understanding of the biomechanical relationship between hip function and lumbar degeneration in patients with chronic low back pain.

Study Type

Observational

Enrollment (Estimated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adults aged 18-65 years with low back pain and available lumbar MRI scans obtained within the previous 12 months. Participants will undergo clinical assessment for Trendelenburg sign and hip function, and lumbar MRI evaluation for degenerative changes.

Description

Inclusion Criteria:Age between 18 and 65 years. Patients who have previously presented to the clinic with a complaint of low back pain.

Willingness and ability to provide written informed consent for participation in the study.

Availability of lumbar MRI images obtained within the previous 12 months and accessible for evaluation.

-

Exclusion Criteria:Presence of red flag conditions associated with low back pain, including malignancy, infection, acute trauma, or significant neurological deficits.

History of lumbar spine surgery. Structural spinal anomalies such as sacralization or lumbarization. Spinal deformities, including scoliosis. Rheumatologic diseases affecting the spine (e.g., axial spondyloarthritis). Significant radiculopathy or advanced neurological deficits, and the presence of extruded or sequestrated lumbar disc herniation.

Clinically significant lumbar spinal stenosis. Spondylolysis and/or spondylolisthesis. Acute vertebral fracture, compression fracture, or recent fracture associated with severe osteoporosis.

Hip or pelvic conditions that may directly influence the Trendelenburg sign, including:

History of hip arthroplasty or hip surgery, Advanced hip osteoarthritis, Residual deformity following lower-extremity fracture, Significant leg length discrepancy (>2 cm). Systemic or neuromuscular disorders, including multiple sclerosis, myopathies, amyotrophic lateral sclerosis (ALS), stroke, or peripheral neuropathies.

Pregnancy. Severe knee or ankle pathology or other conditions causing substantial gait impairment.

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Presence and Severity of Lumbar Facet Joint Arthropathy
Time Frame: Baseline
Assessment of the presence and severity of lumbar facet joint arthropathy on magnetic resonance imaging (MRI) and its association with Trendelenburg sign positivity.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 4, 2026

Primary Completion (Estimated)

August 25, 2026

Study Completion (Estimated)

October 10, 2026

Study Registration Dates

First Submitted

June 1, 2026

First Submitted That Met QC Criteria

June 1, 2026

First Posted (Actual)

June 5, 2026

Study Record Updates

Last Update Posted (Actual)

June 5, 2026

Last Update Submitted That Met QC Criteria

June 1, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • BAU-FTR-2026-07/04

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared to protect participant confidentiality and in accordance with institutional regulations.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lower Back Pain

Subscribe